Home / Pharmaceuticals / Spinal Muscular Atrophy Treatment Market By Type (Type I Spinal Muscular Atrophy, Type II Spinal Muscular Atrophy, Type III Spinal Muscular Atrophy), By Application (Gene Therapy, Drugs) - Growth, Future Prospects, And Competitive Landscape, 2019-2027

Spinal Muscular Atrophy Treatment Market By Type (Type I Spinal Muscular Atrophy, Type II Spinal Muscular Atrophy, Type III Spinal Muscular Atrophy), By Application (Gene Therapy, Drugs) - Growth, Future Prospects, And Competitive Landscape, 2019-2027

Published: Sep 2019 | Report Code: 59899-09-19

"Spinal muscular atrophy treatment market to exhibit dynamic growth during the forecast period"

The global spinal muscular atrophy treatment market is growing proficiently, expected to grow at a CAGR of 14.5%. Globally, the increasing incidence of SMA along with improved treatment management by innovative gene therapy and drugs will drive the growth of the market. Increasing awareness, FDA approval for new drugs, partnerships for enhanced R&D and private funding will boost the overall demand of SMA treatment on a global scale.

Market Synopsis

Spinal Muscular Atrophy Treatment Market

Get a sample copy for more information

"Type I SMA treatment to witness a significant CAGR"

Growing hospital admissions for type I SMA and its therapeutic treatment generated maximum revenue share in 2018. Increasing incidences of SMA in infants and advancement in gene therapy along with strong pipeline drugs internationally will drive the market growth. New drug development for type II and III will show promising growth in the near future, enhanced joint development programs for innovative therapies will drive the demand in the near future such as Risdiplam (RG7916), Reldesemtiv (CK-2127107), Branaplam (LMI070) and others.

Spinal Muscular Atrophy Treatment Market

Get a sample copy for more information

"Gene therapy treatment to witness a significant CAGR in the near future"

Drugs accounted for the maximum revenue share in 2018. In 2018, drugs emerged as the principal treatment application for spinal muscular atrophy (SMA) since Spinraza (developed by Biogen & Ionis Pharmaceuticals) is the only drug approved till date. Additionally, in May 2019, the U.S. FDA approved Zolgensma® (onasemnogene abeparvovec-xioi) by AveXis (Novartis AG), the first gene therapy for infants (less than 2 years of age) suffering with spinal muscular atrophy. Advancement in gene therapy, FDA approval for new drugs, and strong pipeline products offer a huge advantage in the global SMA treatment market. PTC Therapeutics and F. Hoffmann-La Roche AG proceeded with official plans to file for approval in the U.S. market and Europe by the end of 2019, it would set possible approval for the SMA treatment in the first half of 2020.

Spinal Muscular Atrophy Treatment Market

Get a sample copy for more information

"Increased research and development with strong product pipelines in the developed regions"

Major players in the spinal muscular atrophy treatment market are Biogen Idec., Pfizer Inc., Boehringer Ingelheim, Isis Pharmaceuticals, F. Hoffmann-La Roche, Regeneron Pharmaceuticals, AveXis Inc., Novartis AG and others. Merger and acquisitions, partnerships and improved R&D on spinal muscular atrophy targeted treatments will further drive the overall market growth in the near future. Strong pipeline drugs will enhance the overall treatment management for SMA, such as Zolgensma (Novartis), Branaplam (Novartis), Amifampridine Phosphate (Catalyst Pharmaceuticals), Risdiplam (Hoffmann-La Roche) and others.

Spinal Muscular Atrophy Treatment Market

Historical & Forecast Period

This study report represents analysis for each segment from 2017 to 2027 considering 2018 to be the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period from 2019 to 2027.

Report Scope by Segments

Market Segmentation

 

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 By Type (2017–2027; US$ Mn)
 • Type I
 • Type II
 • Type III

 Application (2017–2027; US$ Mn)
 • Gene Therapy
 • Drugs

 Geography Segment (2017–2027; US$ Mn)
 • North America (U.S., Rest of North America)
 • Europe (U.K., Germany, France, Rest of Europe)
 • Asia Pacific (Japan, China, India, Rest of Asia Pacific)
 • Rest of the World (Middle East & Africa, Latin America)

The current report also comprehends qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints and opportunities that gives a better market understanding of the overall spinal muscular atrophy treatment market. Additionally, the global report also comprises graphical representation of competitive landscape based on their market initiatives and strategies, product portfolio and business strengths.

Key questions answered in this report

  • What are the current market trends and dynamics in the Spinal Muscular Atrophy Treatment market and valuable opportunities for emerging players?
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which by Type segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Spinal Muscular Atrophy Treatment market?
  • What is the market trend and dynamics in emerging markets such as Asia Pacific, Latin America and Middle East & Africa?

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Spinal Muscular Atrophy (SMA) Treatment Market
2.2. Global SMAT Market, by Type, 2018 (US$ Mn)
2.3. Global SMAT Market, Application, 2018 (US$ Mn)
2.4. Global SMAT Market, by Geography, 2018 (US$ Mn)

3. Market Dynamics
3.1. Introduction
3.1.1. Global SMAT Market Value, 2017-2027, (US$ Mn)
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.3. Attractive Investment Proposition, by Geography, 2018
3.4. Market Positioning of Key Players, 2018
3.4.1. Major Strategies Adopted by Key Players

4. Global Spinal Muscular Atrophy Treatment (SMAT) Market, by Type , 2017-2027 (US$ Mn)
4.1. Overview
4.2. Type I Spinal Muscular Atrophy
4.3. Type II Spinal Muscular Atrophy
4.4. Type III Spinal Muscular Atrophy

5. Global Spinal Muscular Atrophy Treatment (SMAT) Market, by Application, 2017-2027 (US$ Mn)
5.1. Gene Therapy
5.2. Drugs

6. North America Spinal Muscular Atrophy Treatment (SMAT) Market Analysis, 2017-2027 (US$ Mn)
6.1. Overview
6.1.1. North America SMAT Market Value and Growth, 2017-2027, (US$ Mn)
6.2. North America SMAT Market Value, By Type, 2017-2027 (US$ Mn)
6.2.1. Market Analysis
6.3. North America SMAT Market Value, Application, 2017-2027 (US$ Mn)
6.3.1. Market Analysis
6.4. North America SMAT Market Value, By Region/Country, 2017-2027 (US$ Mn)
6.4.1. Market Analysis
6.4.2. U.S.
6.4.3. Rest of North America

7. Europe Spinal Muscular Atrophy Treatment (SMAT) Market Analysis, 2017-2027 (US$ Mn)
7.1. Overview
7.1.1. Europe SMAT Market Value and Growth, 2017-2027, (US$ Mn)
7.2. Europe SMAT Market Value, By Type, 2017-2027 (US$ Mn)
7.2.1. Market Analysis
7.3. Europe SMAT Market Value, Application, 2017-2027 (US$ Mn)
7.3.1. Market Analysis
7.4. Europe SMAT Market Value, By Region/Country, 2017-2027 (US$ Mn)
7.4.1. Market Analysis
7.4.2. U.K.
7.4.3. Germany
7.4.4. France
7.4.5. Rest of Europe

8. Asia Pacific Spinal Muscular Atrophy Treatment (SMAT) Market Analysis, 2017-2027 (US$ Mn)
8.1. Overview
8.1.1. Asia Pacific SMAT Market Value and Growth, 2017-2027, (US$ Mn)
8.2. Asia Pacific SMAT Market Value, By Type, 2017-2027 (US$ Mn)
8.2.1. Market Analysis
8.3. Asia Pacific SMAT Market Value, Application, 2017-2027 (US$ Mn)
8.3.1. Market Analysis
8.4. Asia Pacific SMAT Market Value, By Region/Country, 2017-2027 (US$ Mn)
8.4.1. Market Analysis
8.4.2. Japan
8.4.3. China
8.4.4. India
8.4.5. Rest of Asia Pacific

9. Rest of the World Spinal Muscular Atrophy Treatment (SMAT) Market Analysis, 2017-2027 (US$ Mn)
9.1. Overview
9.1.1. Rest of the World SMAT Market Value and Growth, 2017-2027, (US$ Mn)
9.2. Rest of the World SMAT Market Value, By Type, 2017-2027 (US$ Mn)
9.2.1. Market Analysis
9.3. Rest of the World SMAT Market Value, Application, 2017-2027 (US$ Mn)
9.3.1. Market Analysis
9.4. Rest of the World SMAT Market Value, By Region, 2017-2027 (US$ Mn)
9.4.1. Market Analysis
9.4.2. Middle East & Africa
9.4.3. Latin America

10. Company Profiles
10.1. Biogen Idec.
10.2. Pfizer Inc.
10.3. Boehringer Ingelheim
10.4. Isis Pharmaceuticals
10.5. F. Hoffmann-La Roche
10.6. Regeneron Pharmaceuticals
10.7. AveXis Inc.
10.8. Novartis AG

* Here we are using SMAT as a short form of Spinal Muscular Atrophy Treatment

FIG. 1 Global Spinal Muscular Atrophy Treatment (SMAT) Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global SMAT Market Segmentation
FIG. 4 Global SMAT Market, by Type, 2018 (US$ Mn)
FIG. 5 Global SMAT Market, by Application, 2018 (US$ Mn)
FIG. 6 Global SMAT Market, by Geography, 2018 (US$ Mn)
FIG. 7 Attractive Investment Proposition, by Geography, 2018
FIG. 8 Global Market Positioning of Key SMAT Market Manufacturers, 2018
FIG. 9 Global SMAT Market Value Share, by Type, 2018 & 2027 (Value %)
FIG. 10 Global Type I SMA Market, 2017–2027 (US$ Mn)
FIG. 11 Global Type II SMA Market, 2017–2027 (US$ Mn)
FIG. 12 Global Type II SMA Market, 2017–2027 (US$ Mn)
FIG. 13 Global SMAT Market Value Share, by Application, 2018 & 2027 (Value %)
FIG. 14 Global GeneTherapy Market For SMA, 2017–2027 (US$ Mn)
FIG. 15 Global Drugs Market For SMA, 2017–2027 (US$ Mn)
FIG. 16 North America SMAT Market, 2017–2027 (US$ Mn)
FIG. 17 Europe SMAT Market, 2017–2027 (US$ Mn)
FIG. 18 Asia Pacific SMAT Market, 2017–2027 (US$ Mn)
FIG. 19 RoW SMAT Market, 2017–2027 (US$ Mn)

TABLE 1 Market Snapshot: Global Spinal Muscular Atrophy Treatment (SMAT) Market
TABLE 2 Impact Indicators
TABLE 3 Impact Analysis of Drivers and Restraints
TABLE 4 Global SMAT Market, by Type, 2017–2027 (US$ Mn)
TABLE 5 Global SMAT Market, by Application, 2017–2027 (US$ Mn)
TABLE 6 Global SMAT Market, by Geography, 2017–2027 (US$ Mn)
TABLE 7 North America SMAT Market, by Type, 2017–2027 (US$ Mn)
TABLE 8 North America SMAT Market, by Application, 2017–2027 (US$ Mn)
TABLE 9 North America SMAT Market, by Country, 2017–2027 (US$ Mn)
TABLE 10 Europe SMAT Market, by Type, 2017–2027 (US$ Mn)
TABLE 11 Europe SMAT Market, by Application, 2017–2027 (US$ Mn)
TABLE 12 Europe SMAT Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 13 Asia Pacific SMAT Market, by Type, 2017–2027 (US$ Mn)
TABLE 14 Asia Pacific SMAT Market, by Application, 2017–2027 (US$ Mn)
TABLE 15 Asia Pacific SMAT Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 16 Rest of the World SMAT Market, by Type, 2017–2027 (US$ Mn)
TABLE 17 Rest of the World SMAT Market, by Application, 2017–2027 (US$ Mn)
TABLE 18 Rest of the World SMAT Market, by Region, 2017–2027 (US$ Mn)
TABLE 19 Biogen Idec.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 20 Pfizer Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 21 Boehringer Ingelheim: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 22 Isis Pharmaceuticals: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 23 F. Hoffmann-La Roche: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 24 Regeneron Pharmaceuticals: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 25 AveXis Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 26 Novartis AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients